KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Cash & Equivalents (2016 - 2025)

Vertex Pharmaceuticals has reported Cash & Equivalents over the past 17 years, most recently at $5.1 billion for Q4 2025.

  • Quarterly results put Cash & Equivalents at $5.1 billion for Q4 2025, up 11.27% from a year ago — trailing twelve months through Dec 2025 was $5.1 billion (up 11.27% YoY), and the annual figure for FY2025 was $5.1 billion, up 11.27%.
  • Cash & Equivalents for Q4 2025 was $5.1 billion at Vertex Pharmaceuticals, up from $4.9 billion in the prior quarter.
  • Over the last five years, Cash & Equivalents for VRTX hit a ceiling of $11.1 billion in Q3 2023 and a floor of $4.6 billion in Q4 2024.
  • Median Cash & Equivalents over the past 5 years was $6.5 billion (2021), compared with a mean of $7.3 billion.
  • Biggest five-year swings in Cash & Equivalents: soared 75.44% in 2021 and later crashed 55.93% in 2024.
  • Vertex Pharmaceuticals' Cash & Equivalents stood at $6.8 billion in 2021, then surged by 54.58% to $10.5 billion in 2022, then fell by 1.28% to $10.4 billion in 2023, then crashed by 55.93% to $4.6 billion in 2024, then grew by 11.27% to $5.1 billion in 2025.
  • The last three reported values for Cash & Equivalents were $5.1 billion (Q4 2025), $4.9 billion (Q3 2025), and $5.0 billion (Q2 2025) per Business Quant data.